Plain-English translation of NCT05592626 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called (also called invikafusp alfa) that works by activating your immune system to fight advanced solid tumors. The study has two parts: first, researchers will slowly increase doses to find the safest and most effective dose, then they will give that dose to more patients to see how well the medication works. The treatment is given by infusion directly into your vein.
Many patients with advanced solid tumors run out of effective treatment options when standard therapies stop working or cause too many side effects. This medication takes a new approach by harnessing your immune system in a different way, and this trial aims to see if it can help patients who have limited options.
You likely qualify if…
You likely don't qualify if…
In the first part of the study, you will receive intravenous infusions of the medication at gradually increasing doses while researchers monitor your safety and side effects. Once a safe dose is identified, the second part enrolls more patients who receive that established dose. You will have regular visits for blood tests, physical exams, and imaging scans to check how your tumor is responding and watch for any side effects. The study will track how long you benefit from treatment and whether your disease stays under control.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States